Skip to main content
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. — Investor Relations & Filings

Ticker · DNLI ISIN · US24823R1059 LEI · 549300ZTQ2HO18L3Q830 US Manufacturing
Open in API
Filings indexed 749 across all filing types
Latest filing 2023-06-06 Director's Dealing
Country US United States of America
Listing US DNLI

About Denali Therapeutics Inc.

https://www.denalitherapeutics.com

Denali Therapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases, lysosomal storage disorders, and other serious illnesses. The company's core scientific strategy centers on its proprietary Transport Vehicle™ (TV) platform, which is engineered to transport large therapeutic molecules, such as antibodies and enzymes, across the blood-brain barrier. This technology is designed to overcome a primary obstacle in treating diseases of the central nervous system. Denali's pipeline comprises a portfolio of investigational drug candidates that leverage this platform to target the underlying genetic and biological pathways of complex diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-06-06 English
FORM 4
Director's Dealing
2023-06-06 English
FORM 4
Director's Dealing
2023-06-06 English
FORM 4
Director's Dealing
2023-06-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a revision to the clinical development program for a drug (BIIB122) in collaboration with Biogen, including changes to clinical trials. There are no financial statements or detailed financial performance data present. The document is not an earnings release, annual report, or interim report. It is an announcement of a significant event related to the company's operations. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-06-05 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2023, by Denali Therapeutics Inc. It reports the submission of matters to a vote of security holders at the company's annual meeting, including election of directors, ratification of the independent auditor, and advisory vote on executive compensation. The key content is the official results of shareholder votes. There is no detailed financial data or full report content, only voting results. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4638 characters, which is consistent with a voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2023-06-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.